Revaprazan (trade name Revanex) is a drug that reduces
gastric acid secretion which is used for the treatment of
gastritis.[2] It acts as an acid pump antagonist[3] (
potassium-competitive acid blocker). Revaprazan is approved for use in South Korea,[4] but is not approved in Europe or the United States.
^Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625.
doi:
10.1111/j.1440-1746.2010.06408.x.
PMID20880169.
S2CID41932174.
^Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82.
doi:
10.1177/0091270003261321.
PMID14681344.
S2CID19658496.